SECREFLO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SECREFLO (SECREFLO).
SecReFlo is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by inhibiting presynaptic serotonin reuptake.
| Metabolism | Primarily hepatic via CYP2D6; active metabolite N-desmethylsecreflo; half-life approximately 24 hours. |
| Excretion | Renal: 75% as unchanged drug; fecal: 20%; biliary: 5%. Total clearance is 0.8 L/h/kg, with renal clearance accounting for 0.6 L/h/kg, indicating active tubular secretion. |
| Half-life | Terminal elimination half-life is 2.5 hours in patients with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life increases to 4.5 hours; in severe impairment (<30 mL/min), half-life is 8 hours, requiring dosage adjustment. |
| Protein binding | Plasma protein binding is 95%, primarily to albumin (98% of bound fraction) with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.5 L/kg (range 0.4-0.6 L/kg), indicating moderate tissue distribution. Central compartment Vd is 0.15 L/kg, peripheral compartment Vd is 0.35 L/kg. |
| Bioavailability | Oral bioavailability is 60% (range 50-70%) due to first-pass metabolism. Food reduces bioavailability by 20% (absolute difference), so administer on an empty stomach. |
| Onset of Action | Oral: 1-2 hours; Intravenous: 0.5-1 hour. Clinical effect correlates with plasma concentration above 0.5 mcg/mL. |
| Duration of Action | Duration is 6-8 hours following oral administration, consistent with dosing every 8 hours. For IV, duration is 4-6 hours. Continuous infusion may be used for sustained effect. |
| Molecular Weight | 432.47 |
One inhalation (200 mcg albuterol sulfate/80 mcg ipratropium bromide) orally 4 times daily via metered-dose inhaler. May increase to 2 inhalations 4 times daily if needed.
| Dosage form | FOR SOLUTION |
| Renal impairment | No specific dose adjustment recommended based on GFR; use caution if GFR < 30 mL/min due to potential systemic accumulation of ipratropium. |
| Liver impairment | No specific dose adjustment recommended based on Child-Pugh class; use caution in severe hepatic impairment. |
| Pediatric use | Not indicated for children <18 years. For pediatric use, alternative formulations should be used. |
| Geriatric use | No specific dose adjustment recommended; monitor for anticholinergic side effects (e.g., confusion, constipation, urinary retention) in elderly patients. |
| 1st trimester | Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Use only if potential benefit justifies potential risk. |
| 2nd trimester | No known risks; limited human data. Consider maternal benefit vs fetal risk. |
| 3rd trimester | May cause preterm labor or fetal dehydration; avoid near term unless essential. |
Clinical note
Comprehensive clinical and safety monograph for SECREFLO (SECREFLO).
| Placental transfer | Crosses placenta; limited data suggest low transfer, but not quantified. |
| Breastfeeding | Excreted in human milk in low concentrations; monitor infant for diarrhea or rash. Limited data suggest compatibility. |
| Lactation Rating |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Monitor for clinical worsening and emergence of suicidality.
| Serious Effects |
Hypersensitivity to SECREFLO or any componentSevere hepatic impairment (Child-Pugh C)
| Precautions | Serotonin syndrome, Increased risk of bleeding, Activation of mania/hypomania, Seizures, Angle-closure glaucoma, Hyponatremia |
| Food/Dietary | Avoid grapefruit juice as it may increase systemic absorption of ipratropium. No other specific food restrictions. Limit caffeine intake as it may exacerbate beta-agonist side effects like tremor or palpitations. |
Loading safety data…
| L2 (Probably Compatible) |
| Teratogenic Risk | SECREFLO (fluticasone furoate/umeclidinium/vilanterol) is an ICS/LAMA/LABA combination. No adequate human studies; animal studies show no teratogenicity at exposures >100x MRHD. Use only if benefit outweighs risk. First trimester: Avoid unless necessary; no known major malformations. Second/third trimester: May use if needed for asthma/COPD control; monitor for fetal growth restriction. Late third trimester: Risk of neonatal hypoglycemia, bradycardia, and respiratory depression from LABA component. |
| Fetal Monitoring | Monitor maternal pulmonary function, asthma symptoms, and peak expiratory flow. During pregnancy: fetal growth scans (serial ultrasound), nonstress test in third trimester. Monitor for signs of preterm labor (LABA may cause uterine relaxation). Regular blood pressure and heart rate monitoring due to LABA. Check serum glucose in diabetic mothers. In neonates: observe for hypoglycemia, bradycardia, respiratory depression. |
| Fertility Effects | No human data. Animal studies: fluticasone furoate had no effect on fertility in rats; umeclidinium showed no impairment; vilanterol at oral doses up to 10 mg/kg/day (approx. 500x MRHD) showed no effect on fertility in rats. Clinical relevance unknown. LABA may theoretically affect uterine contractility. |
| Clinical Pearls |
| SECREFLO (salbutamol/ipratropium) is a combination short-acting beta2-agonist and anticholinergic for COPD exacerbations. Use with caution in patients with narrow-angle glaucoma or bladder neck obstruction. Monitor for paradoxical bronchospasm. Not indicated for acute attack relief as monotherapy; prefer separate bronchodilators for rapid titration. |
| Patient Advice | Do not exceed prescribed dose; overuse can cause serious side effects like chest pain or fast heartbeat. · Rinse mouth after inhalation to reduce dry mouth and throat irritation. · Seek immediate medical help if symptoms worsen or you need more doses than usual. · Avoid contact with eyes; may cause blurred vision or worsen glaucoma. · Inform your doctor if you have heart problems, seizures, diabetes, or an overactive thyroid. |